Carregant...
TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model
BACKGROUND: Castrate Resistant Prostate Cancer (CRPC) is an advanced disease resistant to systemic traditional medical or surgical castration, and resistance is primarily attributed to reactivation of AR through multiple mechanisms. TMPRSS2-ERG fusions have been shown to regulate AR signaling, inter...
Guardat en:
| Publicat a: | BMC Cancer |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6802314/ https://ncbi.nlm.nih.gov/pubmed/31638934 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-6185-0 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|